menu
    • menu
    [{"orgOrder":0,"company":"Cancer Insight","sponsor":"Genentech | Sellas Life Sciences Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Nelipepimut-S","moa":"ERBB2","graph1":"Oncology","graph2":"Phase II","graph3":"Cancer Insight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cancer Insight \/ Genentech | Sellas Life Sciences Group","highestDevelopmentStatusID":"8","companyTruncated":"Cancer Insight \/ Genentech | Sellas Life Sciences Group"},{"orgOrder":0,"company":"GALENA BIOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Nelipepimut-S","moa":"ERBB2","graph1":"Oncology","graph2":"Phase III","graph3":"GALENA BIOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GALENA BIOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GALENA BIOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Nelipepimut-S","moa":"||ERBB2","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Nelipepimut-S

    Menu

    Nelipepimut-S

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sellas Life Sciences Group

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sellas Life Sciences Group

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelipepimut-S,Sargramostim

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SELLAS Announces Positive Antigen-Specific Immune Response Data for Nelipepimut-S (NPS) in Women

                            Details : Preliminary data show 11-fold increase in CD8 cytotoxic T-lymphocytes immune response in patients who received single dose of NPS compared to baseline.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 18, 2020

                            Lead Product(s) : Nelipepimut-S,Sargramostim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cancer Insight

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Cancer Insight

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelipepimut-S

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Genentech | Sellas Life Sciences Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patie...

                            Details : NeuVax (Nelipepimut-S) is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : NeuVax

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 21, 2014

                            Lead Product(s) : Nelipepimut-S

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Genentech | Sellas Life Sciences Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GALENA BIOPHARMA

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            GALENA BIOPHARMA

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelipepimut-S

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of NeuVaxâ„¢ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

                            Details : NeuVax vaccine (Nelipepimut-S) is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : NeuVax vaccine

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 24, 2011

                            Lead Product(s) : Nelipepimut-S

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth